Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RO7446603 alone or in combination with faricimab/aflibercept in diabetic macular edema
CTR20251430Phase 2Terminated
- Sponsor
- Genentech
- Start
- Jun 2025
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RG6351 in diabetic macular edema (DME), sponsored by Genentech. Started Jun 2025; status: terminated.
02
Drugs
RG6351
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20251430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251430.